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Abstract
Background: Patients with type 2 diabetes mellitus (T2DM) have an increased risk to develop severe diabetes
related complications, especially cardiovascular disease (CVD). The risk to develop CVD can be estimated by means
of risk formulas. However, patients have difficulties to understand the outcomes of these formulas. As a result, they
may not recognize the importance of changing lifestyle and taking medication in time. Therefore, it is important to
develop risk communication methods, that will improve the patients’ understanding of risks associated with having
diabetes, which enables them to make informed choices about their diabetes care.
The aim of this study is to investigate the effects of an intervention focussed on the communication of the abso-
lute 10-year risk to develop CVD on risk perception, attitude and intention to change lifestyle behaviour in patients
with T2DM. The conceptual framework of the intervention is based on the Theory of Planned Behaviour and the
Self-regulation Theory.
Methods: A randomised controlled trial will be performed in the Diabetes Care System West-Friesland (DCS), a
managed care system. Newly referred T2DM patients of the DCS, younger than 75 years will be eligible for the
study. The intervention group will be exposed to risk communication on CVD, on top of standard managed care of
the DCS. This intervention consists of a simple explanation on the causes and consequences of CVD, and
possibilities for prevention. The probabilities of CVD in 10 year will be explained in natural frequencies and
visualised by a population diagram. The control group will receive standard managed care. The primary outcome is
appropriateness of risk perception. Secondary outcomes are attitude and intention to change lifestyle behaviour
and illness perception. Differences between baseline and follow-up (2 and 12 weeks) between groups will be
analysed according to the intention-to-treat principle. The study was powered on 120 patients in each group.
Discussion: This innovative risk communication method based on two behavioural theories might improve
patient’s appropriateness of risk perception and attitude concerning lifestyle change. With a better understanding
of their CVD risk, patients will be able to make informed choices concerning diabetes care.
Trail registration: The trial is registered as NTR1556 in the Dutch Trial Register.
Background
Patients with type 2 diabetes mellitus (T2DM) have an
increased risk to develop severe complications including
cardiovascular disease (CVD). The risk of these compli-
cations can be reduced by an adequate treatment with
medication and by adopting a healthy lifestyle [1-3].
During the last few decades, patients are encouraged to
become more actively involved in diabetes care. It is
now believed that they should be the primary decision-
makers in the control of their diabetes as laid down in
the patient empowerment approach [4,5]. According to
this approach, patients should be encouraged to use
their own ability to gain mastery over their diabetes.
Informing patients on the risks to develop severe
diabetes related complications enables them to make
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informed choices. It has been shown that patients under-
estimate these risks, and that they do not understand the
explanation of caregivers about risks [6-13]. In contrast, it
was also found that some patients are unrealistically pessi-
mistic about their risk to develop CVD, resulting in anxi-
ety [14,15]. Both optimistic and pessimistic patients have a
reluctance in self-management [12-14,16,17]. The risk of
developing complications should be explained in a way
that is understandably for patients, to give them opportu-
nities to make informed choices on their diabetes care.
With clear information on the risk of developing compli-
cations, patients’ risk perception may improve, which may
result in a change in their attitude and intention to change
lifestyle behaviour [12,14,17,18]. Although some caregivers
believe that patients do not desire to take responsibility for
their disease and that this responsibility might harm them
[19], there is evidence that patients welcome the given
responsibility. It is still unclear though how this can be
achieved [20].
Risk communication
Healthcare professionals usually explain numerical risks
of developing diabetes-related complications, in percen-
tages, frequencies, relative risks, absolute risk and ‘num-
ber needed to treat’ [7,21]. However, patients often do
not understand the meaning of these numbers [10,11].
Specific insights on how to communicate health risks
to patients have become available. Firstly, it is important
to provide a clear and very simple message. This message
should consist of information on what causes the risk,
what are the consequences of the risk, and what can be
done to prevent or treat the problem [22-26]. Secondly,
the message should consist the individual risk probability
in formats that patients are more likely to understand
such as a visual presentation of risks rather than a pre-
sentation in percentages [18,21,23,27-32]. It is not clear
what timeline for the risk presentation is preferred, but
most absolute risks on CVD are predicted in a 10-year
time horizon. Thirdly, positive framing, which means
that the benefits of behaviour change are highlighted
instead of a frame that focuses on the effect of not chan-
ging in terms of loss of healthy years of one’s life, seems
to help to increase patients’ motivation [23,28,32-34].
In this study, we will use this broad approach of risk
communication; we will not only focus on the commu-
nication of the actual risk but also on the causes and
consequences of the risk by using the principles of a
simple but complete message, visual representation and
a positive framework to investigate if patients are able
to understand the meaning of risks.
Theoretical framework
The importance of risk communication for patients with
T2DM can be explained by means of a theoretical
framework. The idea is that patients are not willing to
change their lifestyle if they are not informed on the rea-
son why they should change. It is believed that people
have perceptions concerning their disease, either correct
or incorrect. These perceptions determine how people
cope with their disease and how they manage their risks
to develop severe complications. The hypothesis is that
by providing understandable information on the disease
by means of risk communication illness perceptions will
change and, in addition, the attitude of patients concern-
ing the importance of behaviour change.
The conceptual framework for this idea is based on
two theories: the Self-regulation theory of Leventhal
[35-37] and the Theory of Planned Behaviour [38,39].
Leventhal’s Self-regulation Theory assumes that a
patient’s perceptions on the impact of diabetes and its
treatment determine the attitude concerning self-man-
agement. Illness perceptions include the identity, time-
line, cause, consequences and controllability of the
disease [35-37,40].
The attitude to change behaviour is described in the
second theory, the Theory of Planned Behaviour [38,39].
According to this theory, there are three determinants
of intention to change a specific behaviour: a) attitude
towards the behaviour; b) subjective norm which repre-
sent perceived social pressure by significant others to
perform the behaviour, and c) perceived behavioural
control, which refers to the perceived ease or difficulty
to perform the behaviour. For the framework of this
study, it is expected that risk communication will have
impact on the attitude to change behaviour.
The plausibility of our theoretical framework will be
established by measuring the components of the the-
ories by means of questionnaires.
Objectives
The primary objective of this study is to investigate the
effect of a risk communication intervention on appropri-
ateness of risk perception in patients with T2DM. Sec-
ondary objectives are to investigate the effects on illness
perceptions, attitude, and intention to change behaviour.
We will also assess patients’ general satisfaction with the
communication and anxiety to check for adverse effects
of risk communication.
Methods
Design of the study
The study is a randomised controlled trial. The Medical
Ethical Committee of the VU University Medical Center
in Amsterdam approved the study protocol.
Setting
The trial is conducted within ‘the Diabetes Care System
(DCS) West-Friesland’, a managed care system that was
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implemented in The Netherlands in 1997. The DCS was
described previously [41]. Briefly, this care system pro-
vides additional care to that of the general practitioners
(GPs) in the region West-Friesland of the Netherlands.
GPs in the region refer all their T2DM patients to the
DCS. Each patient visits the DCS annually for a physical
examination, followed by a visit to a diabetes nurse and
a dietician for information and advice on their diabetes
treatment. The results of this annual examination are
sent to the patient’s GP, who is responsible for the man-
agement of the patient and delegation of tasks to their
practice nurse, according to the guidelines of the Dutch
College of General Practitioners [42]. These guidelines
recommend every patient with diabetes to visit a GP
every 3 months. The well-organised infrastructure of the
DCS with experienced medical assistants, diabetes
nurses, and dieticians provides a suitable setting to
implement a new intervention for patients with diabetes.
Study population
The study population consist of newly referred patients
with type 2 diabetes to the DCS. Inclusion criteria are:
maximum age of 75 years and capable to fill in question-
naires in the Dutch language. Patients that have experi-
enced a cerebrovascular accident or transient ischaemic
attack will be excluded from participation in the study
because they might have communication problems.
Patients with other CVD may participate in the study.
Patients that fulfil the inclusion criteria will be sent an
information letter as well as a concept of the informed
consent form of the study. Subsequently, the patient will
visit the medical assistant for their annual physical
examination of the DCS concerning their standard care.
In this visit, the medical assistant will also explain the
purpose of the study and interest to participate in the
study will be asked. All participating patients must sign
a written informed consent form. After that, physical
measurements are performed, which include body
weight, blood pressure, and drawing of blood samples
(to assess fasting blood glucose, HbA1c, total choles-
terol, HDL-cholesterol and triglycerides). In addition,
patients are given the first self-administrated question-
naire to fill in at the DCS.
Treatment allocation
For intervention allocation a randomization list is drawn
up using a computerized randomization computer pro-
gram (Random Allocation Software version 1.0.0).
Patients are randomly assigned to either the intervention
group, receiving the risk communication intervention in
addition to the managed diabetes care or the control
group, receiving managed diabetes care only. Approxi-
mately two weeks after the first visit, patients are sched-
uled for either the intervention or control session to the
diabetes nurse and dietician. The manager of the DCS,
who is not involved in the patients’ care, allocates the
patient to one of the two groups on the basis of the ran-
domisation list. The flow of the patients will be regis-
tered by a medical assistant according to a flow diagram
recommended by the CONSORT statement [43]. Parti-
cipants may withdraw from the study at their own
request and without providing reasons. Provided reasons
for withdrawal will be registered. Figure 1 shows the
design of the study.
Blinding
Patients, diabetes nurses and dieticians cannot be
blinded to the intervention. The principal investigator
(LMCW) remains blinded during the entire intervention.
Interventions
Control group
Patients allocated to the control group receive managed
diabetes care provided by the DCS. Patients are invited
for a physical examination at the DCS. One or two
weeks later, the patient visits a diabetes nurse and dieti-
cian, for 30 minutes each, in order to receive results
from the physical examination, including an explanation
of high and low values of the different lab results such
as HbA1c and cholesterol, and general information and
education on diabetes problems, dietary intake and phy-
sical activity.
Follow-up visits to the DCS are optional if desired. In
addition, the patients will visit the GP every 3 months
according to the guidelines of the Dutch College of
General Practitioners [42].
Intervention group
Patients who are assigned to the intervention group will
receive a risk communication intervention in addition to
the managed care of the DCS. This means that these
patients will also be invited for a physical examination,
followed by a visit to the diabetes nurse and dietician,
also for 30 minutes each. This visit will consist of the
risk communication intervention (see below) followed
by standard care of DCS. The diabetes nurses and dieti-
cians will receive training in performing the interven-
tion. Follow-up visits to the DCS are optional for
patients in the intervention group as well. The risk com-
munication intervention will not be performed again in
follow-up visits. In addition, these patients will also visit
the GP every 3 months according to the guidelines of
the Dutch College of General Practitioners [42].
The risk communication consists of the previously
described principles: a simple message including the
cause and consequences of the risk and possibilities to
improve the risk, explaining the absolute 10-year risk in
natural frequencies and visual representation (popula-
tion diagram), and positive framing (gain versus loss).
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The intervention starts at the diabetes nurse. By
means of nine variables (age at diagnosis, duration of
diabetes, sex, ethnicity, smoking status, systolic blood
pressure, HbA1c, total cholesterol, and HDL-cholesterol)
the risk to develop CVD will be estimated with the
UKPDS risk engine [44]. The diabetes nurse will explain
the meaning of this risk according to an intervention
protocol with six steps:
1) The introduction of the risk communication This
step includes a general explanation about health related
risks concerned with T2DM, including the cause and
consequences of the CVD risk. This step is focused on
the dimension ‘cause’ and ‘consequences’ from the Self-
regulation Theory [35].
2) Communication of the absolute risk according to
the UKPDS risk engine In this step, the absolute risk to
develop CVD in the next 10 years will be explained in
the format of natural frequencies. For example, the fol-
lowing sentence will be used: “Your risk to develop
CVD in the next 10 years is X%. This means that of the
100 men/women of your age and with the same lab
results and who also smoke/do not smoke, × will
develop CVD in the next 10 years”.
3) Visual communication by means of a risk card In
this step, the risk will be explained again with the help
of a population diagram. This diagram shows 100 people
and the diabetes nurse indicates which people will
develop CVD in the next 10 years.
4) Positive framing: explanation that lifestyle changes
can help to reduce the risk The following step is ‘mes-
sage framing’: translate the risk estimation into a posi-
tive message. The risk has a negative character but in
Visit 1 (week 0): physical examination
Randomisation
Written informed consent and baseline 
questionnaire
Patiënt is not willing to 
participate
Control Group:
Visit 2 (week 1-2)  standard care 
from the DCS at diabetes nurse and 
dietician
Newly referred patient < 75 years old, 
participating in the diabetes care system
Intervention group:
Visit 2 (week 1-2)  standard care 
from the DCS at diabetes nurse and 
dietician and intervention on risk 
communication
Questionnaire 2 (week 1-2): 
directly after visit 2
Questionnaire 3 (week 12)
Questionnaire 2 (week 1-2):  
directly after visit 2
Questionnaire 3 (week 12)
Patient is not eligible: has 
experienced a TIA or CVA
Figure 1 Design of the randomised controlled trial on the effects of risk communication in patients with type 2 diabetes.
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this step will be explained that the patient is able to
change the risk. In addition, the message will include
the possibilities of how to change the risk. It is esti-
mated that the risk to develop CVD in the next 10 years
can be reduced by 30% by changing lifestyle habits, such
as increasing physical activity, eating a healthier diet and
to quit smoking. For example, a risk of 30% can be
reduced to 21%. This means that the absolute health
gain is 9%. The diabetes nurses will show this on the
risk card by indicating the people that will no longer be
at risk to develop CVD. In this example, 9 people will
be indicated. This step is based on the dimension ‘con-
trollability’ of the Self-regulation Theory [35].
5) Communication with the patient for a reaction
After having finished the explanation of the risk, the
diabetes nurse will ask the patient to give a reaction on
the information that has been given using open
questions.
6) Think aloud: patient has to explain the risk him/
herself The patient will be encouraged to ‘think aloud’
about the risk and the meaning of the risk. It is believed
that active participation will enable the patient to
remember the information more easily [45].
Subsequently, the patient visits the dietician, who will
continue the intervention. The dietician will start with
step 6 of the intervention, the ‘think aloud method’ to
see if the patient is able to explain what he/she has
learned about his/her CVD risk. Depending on the
answer of the patient, the dietician will choose one of
the next steps:
• If the patient explains the CVD risk and what he/
she can do to change the risk accurately, the dieti-
cian will confirm this. The remaining time of the
visit will then be used for general diabetes related
information and education on dietary intake and
physical activity.
• If the patient is not able to explain the CVD risk
or the possibilities of changing the risk, the dietician
will repeat the risk communication, starting at step
2. Next, the dietician will provide usual care of the
DCS on dietary intake and physical activity.
All steps will carefully be registered in order to use
this information in the analysis.Training of the diabetes
nurses and dieticians
The diabetes nurses and dieticians received a training
consisting of the following subsequent parts:
1) Training 1: a half day training by an experienced
communication coach in health care settings and the
principal investigator (LMCW). The training con-
sisted of an introduction on the importance of pro-
viding information to the patients on risks and
theory on risks communication, including the defini-
tion of a risk, an explanation of absolute and relative
risks, methods of risk communication and the Self-
regulation Theory and Theory of Planned Behaviour.
In addition, the UKPDS risk engine was explained
including the scientific background of its develop-
ment. The last part of this day consisted of an expla-
nation of the intervention. In order to increase
treatment fidelity to the intervention, attention was
also paid to the usual care for the control group,
which is standardised by means of a protocol. This
training day ended with practising the intervention
steps by means of role plays.
2) Pilot study: a pilot study was performed to give
diabetes nurses and dieticians the opportunity to
learn their skills. The coach attended visits with two
patients of each diabetes nurse and dietician (’coach-
ing-on-the-job’). She checked all steps of the inter-
vention and the general quality of the
communication and provided feedback immediately
after each visit.
3) Training 2: another half day by the coach and
principal investigator. During this training the coach
discussed the most important issues that occurred
during the pilot study to the whole group.
The training was guided by a handbook developed by
the researchers and the coach including the theoretical
background of risks and risk communication, the proto-
col for the intervention and control group, the risk card,
and the role plays.
Treatment fidelity
All diabetes nurses and dieticians were trained to per-
form the intervention and they all have contact with
patients of both the intervention and control group.
Due to practical reasons, (i.e the part-time availability of
the diabetes nurses and dieticians) it was not possible to
divide the caregivers into two groups.
To increase treatment fidelity we will take two mea-
sures. Firstly, we developed a protocol for both the
intervention and control group that is obliged to use
during the whole study period by all diabetes nurses
and dieticians. Secondly, 20 tape-recordings (10 inter-
vention patients and 10 control patients) are made to
assess treatment fidelity of the diabetes nurses and
dieticians.
Outcome assessment
Primary and secondary outcome measurements are
assessed at baseline, and again after 2 weeks (directly
after the intervention or control visit to the diabetes
nurse and dietician) and 12 weeks by means of self-
reported questionnaires.
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Primary outcome measure
Appropriateness of risk perception is the primary out-
come measure. Risk perception will be measured by
using a question from a questionnaire previously devel-
oped for the IMPALA study [46]. This question is ‘If
the mean risk of developing CVD in the next 10 years
for men with diabetes is 20 of 100 men and for women
15 of 100 women, how would you rate your risk of
developing CVD in the next 10 years?’ In addition, at 2
and 12 weeks only, a population diagram will also be
shown in the questionnaire. Patients will be asked to
indicate how many of 100 people will develop CVD in
the next 10 years.
Appropriateness of risk perception will be assessed by
a comparison of the UKPDS score [44] of the patient
with the risk perception. Appropriateness is considered
as a patient with a high-risk perception while indeed
having a high risk, or a patient with a low-risk percep-
tion while having a low risk [46]. According to the
UKPDS risk engine, a risk of > 30% is considered high
risk, a risk between 15 and 30% is an intermediate risk,
a risk < 15% is a low risk.
Secondary outcome measures
1. Anxiety and worry about CVD risk is assessed by a 7-
point Likert scale, ranging from ‘not anxious/worried at
all’ to ‘very worried/anxious’. These questions were used
in an earlier study by Claassen et al. [13].
2. Illness perception is assessed by the Brief Illness
Perception Questionnaire (Brief-IPQ) [47]. The Brief-
IPQ consist of 8 items on the seriousness and impact of
diabetes on various aspects of life, measured on a 10-
point Likert scale ranging from ‘strongly disagree’ to
‘strongly agree’. There is also 1 open question that asks
patients to list what they consider the three most impor-
tant causes for their disease.
3. Attitude and intention to change behaviour accord-
ing to the Theory of Planned Behaviour [38] are mea-
sured by the Determinants of Lifestyle Behaviour
Questionnaire, which was developed for a randomised
controlled trial to investigate the effects of a cognitive
behaviour programme on the primary prevention of
T2DM and CVD [48]. The questionnaire consists of
three parts, namely on the attitude and intention to
change 1) dietary intake, 2) physical activity and 3)
smoking behaviour. Each part has seven attitude items
and three items on intention to change the specific
behaviour. The attitude items have a 7-point scale.
Examples of attitude items are: ‘I consider eating heal-
thier/increasing physical activity/quitting smoking good-
bad, difficult-easy, frustrating-satisfactory’. The intention
to change behaviour items have a 5-point Likert scale
ranging from ‘strongly agree’ to ‘strongly disagree’. An
example is ‘I intend to eat healthier/increase physical
activity/stop smoking within two months’.
4. The Short Form Spielberger State Anxiety Inventory
(SF-STAI) [49] consists of six items to assess the extent
to which patients feel ‘calm’, ‘tense’, ‘upset’, ‘relaxed’,
‘content’, and ‘worried’ on a 4-point scale ranging from
‘not at all’ to ‘very much’. Sum scores will range
between 20 and 80 with higher scores indicating higher
levels of anxiety.
5. Satisfaction with the communication is assessed by
questions from the COMRADE scale [46]. This scale
consists of 10 questions on a 5-point scale ranging from
‘strongly disagree’ to ‘strongly agree’. These questions
are only included in the second questionnaire, which is
given at 2 weeks just after the visit to the diabetes nurse
and dietician.
Additional measurements
Physical examinations will be performed and blood sam-
ples are taken at baseline by medical assistants of the
DCS at baseline in order to estimate the risk to develop
cardiovascular disease by means of the UKPDS risk
engine [44]. Systolic blood pressure is measured after 5
minutes of rest in seated position by Collon Press mate
(BP-8800, Komaki-City). HbA1c will be measured by
High Performance Liquid Chromatography and total
cholesterol and HDL-cholesterol by means of enzymatic
techniques (Boehringer-Mannheim, Mannheim, Ger-
many). Age, duration of diabetes, sex, ethnicity, level of
education, marital or cohabiting status, employment sta-
tus, family history of T2DM and CVD and smoking sta-
tus are included in the self-reported questionnaires.
Smoking status will be distinguished in non-smoker,
ex-smoker or current smoker including number of
cigarettes per day.
Sample size
The primary outcome measure is risk perception.
Because we do not have the availability of a validated
questionnaire it is not possible to use data of previous
studies for the purpose of the power calculation. There-
fore, we choose to use Cohen’s effect sizes [50]. The
power calculation is based on a difference of 0.5 stan-
dard deviations between the intervention and control
group. The calculation is based on the Student’s t-test
for two independent groups.
The result is that we need 84 patients in each group
to detect a difference of half a standard deviation with a
power of 90%. Taking into account a possible dropout
rate of 30% the number of patients in each group must
be 120. In 2008, approximately 40 newly diagnosed
patients per month were registered at the DCS, which
means 480 patients per year. It is expected that not all
patients are eligible and willing to participate in the
study and therefore we preserve an inclusion period of
12 months.
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Analyses
Comparability between the two groups will be assessed
at baseline. On the basis of an intention-to-treat analy-
sis, differences in changes between the intervention and
the control group are measured with 95% confidence
intervals at 2 and 12 weeks for both primary and sec-
ondary outcomes. For dichotomous outcome variables
multilevel logistic regression analyses will be used. To
calculate differences between continuous variables linear
regression analyses will be used. If there are any relevant
differences between the groups, we will adjust data for
these factors (i.e. age, gender, diabetes duration, level of
education and family history regarding T2DM and
CVD).
Discussion
This article contains an extensive description of the
design of the @RISK Study: an intervention to investi-
gate the effects of a newly designed risk communication
protocol on risk perception, attitude and intention to
change lifestyle behaviour. We expect that due to the
risk communication intervention, patients’ appropriate-
ness of risk perception will improve in a way that they
will understand the meaning of their absolute 10 year
risk to develop CVD, and subsequently develop a more
positive attitude and intention towards lifestyle beha-
viour change. Risk communication is very relevant and
important for patients with diabetes because nowadays
patients are expected to make their own choices and
decisions concerning their diabetes care.
Only a few studies on the effectiveness of risk com-
munication on changing patients’ risk perception and
attitude on lifestyle changes have been performed. Bren-
ner et al. performed a randomised controlled trial on
risk communication in patients with hypertension and a
CVD risk > 10%. The intervention included educating
patients of their 10-year risk of myocardial infarction or
death, illustrated by a graphical representation of the
risk, and three follow-up phone calls by a physician or
study nurse. This resulted in behaviour modification
and in a significant reduction in CVD risk [51,52]. A
randomised controlled trial by Koelewijn-van Loon et al.
found that appropriateness of risk perception improved
and anxiety reduced. They found no improvement in
lifestyle in patients with high risk of developing CVD.
As the risk communication was part of a large interven-
tion study, it is unclear if the risk communication itself
has caused the improvement [46,53].
To our knowledge, evidence on this topic for patients
with T2DM is scarce and this study might have an
important contribution to the research in this field.
Only two studies have been performed on patients with
T2DM. Asimakopoulou et al. studied the impact of risk
communication by means of a combination of visual
tools of developing CHD in patients with T2DM. They
found that patients improved their risk perception and
they were able to recall their risk after six weeks [54].
Edwards et al. evaluated different risk presentation for-
mats in patients with diabetes and showed that patients
found graphical representations helpful and had no clear
preference for which graphical tool, however it did not
change patients’ ability to make decisions on their health
[18]. These two studies were not based on theory, which
makes it difficult to untangle the mechanism of risk per-
ception in relation to self-management. In addition, the
purpose of the study of Edwards et al. was to investigate
which kind of graphical information was most helpful
and not really the risk communication itself.
The key element of this trial is the use of a theoretical
framework, based on the Theory of Planned Behaviour
[38,39] and the Self-regulation Theory [35-37]. Elements
of the intervention are based on the theoretical frame-
work. Communication of absolute risk is based on the
illness perception ‘cause’ of the Self-regulation Theory
and the communication by means of a positive message
is focused on the ‘controllability’ of the theory. This
message tells patients that they can control their disease
themselves.
The population diagram used in this study was already
found to be feasible in the IMPALA study [46], which is
a trial on the implementation of a nurse-led intervention
for cardiovascular risk management in primary care.
Their risk communication tool was tested in a pilot
study. The risk tool in IMPALA also consisted of a bar
chart to explain the possibilities for risk reduction also
by relative risk reduction, but process evaluation showed
that this was hardly used by the nurses in the IMPALA
study.
In this study, much attention is paid to the diabetes
nurses’ and dieticians’ skills to perform the intervention
by means of a training program and pilot study. The
main strength of this part of the study is the availability
of an experienced communication coach who has been
performing ‘coaching-on-the-job’. This will improve the
quality and standardisation of the intervention, rather
than supervision in groups, lacking personal feedback to
the caregivers.
A limitation of the study design is that we were not
able to divide the diabetes nurses and dieticians into
two groups: one group that performs the intervention
and one group that takes care of the control group. The
reason for this limitation is a practical one: we imple-
mented the study into the DCS in which diabetes nurses
and dieticians work part-time. If we trained only half of
the diabetes nurses and dieticians employed at the DCS,
the intervention could not be performed every day of
the week. This would cause problems in scheduling the
patients, which is likely to influence their willing to
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participate in the study. Therefore, we decided to train
all diabetes nurses and dieticians. To increase treatment
fidelity we developed both an intervention and a control
group protocol. In addition, we will make tape record-
ings to assess treatment fidelity.
This study started at the end of 2008 with the training
of the diabetes nurses and dieticians, followed by the
pilot study. The inclusion of patients started in March
2009 and will continue through February 2010. Results
will become available at the end of 2010.
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